Alnylam to webcast conference call discussing fourth quarter and full
year 2013 financial results
Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), a leading rnai therapeutics company, today announced that it will report financial results for the fourth quarter and year ending december 31, 2013 on thursday, february 13, 2014, after the u.s. financial markets close. management will provide an update on the company, discuss fourth quarter and year-end 2013 results, and discuss expectations for the future via conference call on thursday, february 13, 2014 at 4:30 p.m. et. to access the call, please dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes prior to the start time and refer to conference id 46682151. a replay of the call will be available beginning at 7:30 p.m. et on february 13, 2014. to access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer to conference id 46682151. a live audio webcast of the call will also be available on the news & investors section of the company’s website, www.alnylam.com. an archived webcast will be available on the alnylam website approximately two hours after the event. about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference, or rnai. the company is leading the translation of rnai as a new class of innovative medicines with a core focus on rnai therapeutics as genetic medicines, including programs as part of the company’s “alnylam 5x15tm” product strategy. alnylam’s genetic medicine programs are rnai therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. these include: patisiran (aln-ttr02), an intravenously delivered rnai therapeutic targeting transthyretin (ttr) for the treatment of ttr-mediated amyloidosis (attr) in patients with familial amyloidotic polyneuropathy (fap); aln-ttrsc, a subcutaneously delivered rnai therapeutic targeting ttr for the treatment of attr in patients with familial amyloidotic cardiomyopathy (fac); aln-at3, an rnai therapeutic targeting antithrombin (at) for the treatment of hemophilia and rare bleeding disorders (rbd); aln-cc5, an rnai therapeutic targeting complement component c5 for the treatment of complement-mediated diseases; aln-as1, an rnai therapeutic targeting aminolevulinate synthase-1 (alas-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (aip); aln-pcs, an rnai therapeutic targeting pcsk9 for the treatment of hypercholesterolemia; aln-aat, an rnai therapeutic targeting alpha-1-antitrypsin (aat) for the treatment of aat deficiency liver disease; aln-tmp, an rnai therapeutic targeting tmprss6 for the treatment of beta-thalassemia and iron-overload disorders; and aln-ang, an rnai therapeutic for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia, amongst other programs. as part of its “alnylam 5x15” strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in phase 3 and five to six programs with human proof of concept - by the end of 2015. the company’s demonstrated commitment to rnai therapeutics has enabled it to form major alliances with leading companies including merck, medtronic, novartis, biogen idec, roche, takeda, kyowa hakko kirin, cubist, glaxosmithkline, ascletis, monsanto, the medicines company, and genzyme, a sanofi company. in january 2014, alnylam agreed to acquire sirna therapeutics, a wholly owned subsidiary of merck. in addition, alnylam holds an equity position in regulus therapeutics inc., a company focused on discovery, development, and commercialization of microrna therapeutics. alnylam scientists and collaborators have published their research on rnai therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as nature, nature medicine, nature biotechnology, cell, the new england journal of medicine, and the lancet. founded in 2002, alnylam maintains headquarters in cambridge, massachusetts. for more information, please visit www.alnylam.com.
